Browse By Cell Line Result Page of OvirusTdb

The total number of records retrieved from this search are 28. Click on ID to see further detail.
IDOV_943Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 virus particle/cellIn-vitro result80% cancer cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_944Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 virus particle/ cellIn-vitro result70% cancer cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_945Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 virus particle/ cellIn-vitro result70% cancer cell survival after 6 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_946Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 virus particle/ cellIn-vitro result80% cancer cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_975Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 virus particle/cellIn-vitro result80% cancer cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_976Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 virus particle/ cellIn-vitro result80% cancer cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_977Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 virus particle/ cellIn-vitro result50% cancer cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_978Virus nameAdenovirusVirus strainwild typeVirus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineAlabama-BirminghamOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 virus particle/ cellIn-vitro result20% cancer cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1055Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 pfu/cellIn-vitro result100% cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1056Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 pfu/cellIn-vitro result80% cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1057Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 pfu/cellIn-vitro result75% cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1058Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 pfu/cellIn-vitro result30% cell survival after 2 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1059Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 pfu/cellIn-vitro result100% cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1060Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 pfu/cellIn-vitro result20% cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1061Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 pfu/cellIn-vitro result20% cell survival after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1062Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 pfu/cellIn-vitro result100% cell killing after 4 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1063Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 pfu/cellIn-vitro result100% cell survival after 6 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1064Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 pfu/cellIn-vitro result100% cell killing after 6 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1065Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 pfu/cellIn-vitro result100% cell killing after 6 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1066Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 pfu/cellIn-vitro result100% cell killing after 6 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1067Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10 pfu/cellIn-vitro result100% cell survival after 8 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1068Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration100 pfu/cellIn-vitro result100% cell killing after 8 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1069Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration1000 pfu/cellIn-vitro result100% cell killing after 8 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_1070Virus nameHerpes simplex virusVirus strainHSV-1Virus genome typeDNAVirus familyHerpesviridaeVirus genome modificationMutant NV1066Virus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineMediGene Inc. San Diego, CAOrigin of cell lineNeuroblastoma cell lineCell lineSKNBEConcentration of cell line4.0E+3 cells per wellIn-vitro toxicityNAAssayNAIn-vitro virus concentration10000 pfu/cellIn-vitro result100% cell killing after 8 daysModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedApoptosis induction and cspase 3 activationImmunogenic effectNAClinical trialNAPMID15570577
IDOV_2891Virus nameVaccinia virusVirus strainvvDDVirus genome typeDNAVirus familyPoxviridaeVirus genome modificationDeletion of TK gene and vaccinia growth factorVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineLaboratory grown own cultureOrigin of cell lineNeuroblastoma cell lineCell lineSKNBE2Concentration of cell line5.0E+3 cells per wellIn-vitro toxicityNAAssayMTT assayIn-vitro virus concentration0.01 MOIIn-vitro result50% cell survivalModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedNAImmunogenic effectNAClinical trialNAPMID23816608
IDOV_2892Virus nameVaccinia virusVirus strainvvDDVirus genome typeDNAVirus familyPoxviridaeVirus genome modificationDeletion of TK gene and vaccinia growth factorVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineLaboratory grown own cultureOrigin of cell lineNeuroblastoma cell lineCell lineSKNBE2Concentration of cell line5.0E+3 cells per wellIn-vitro toxicityNAAssayMTT assayIn-vitro virus concentration0.1 MOIIn-vitro result40% cell survivalModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedNAImmunogenic effectNAClinical trialNAPMID23816608
IDOV_2893Virus nameVaccinia virusVirus strainvvDDVirus genome typeDNAVirus familyPoxviridaeVirus genome modificationDeletion of TK gene and vaccinia growth factorVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineLaboratory grown own cultureOrigin of cell lineNeuroblastoma cell lineCell lineSKNBE2Concentration of cell line5.0E+3 cells per wellIn-vitro toxicityNAAssayMTT assayIn-vitro virus concentration1 MOIIn-vitro result38% cell survivalModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedNAImmunogenic effectNAClinical trialNAPMID23816608
IDOV_2894Virus nameVaccinia virusVirus strainvvDDVirus genome typeDNAVirus familyPoxviridaeVirus genome modificationDeletion of TK gene and vaccinia growth factorVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineLaboratory grown own cultureOrigin of cell lineNeuroblastoma cell lineCell lineSKNBE2Concentration of cell line5.0E+3 cells per wellIn-vitro toxicityNAAssayMTT assayIn-vitro virus concentration10 MOIIn-vitro result20% cell survivalModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedNAImmunogenic effectNAClinical trialNAPMID23816608